Protein and non-protein biomarkers in melanoma: A critical update

Amino Acids

Volumn 43, Issue 6, 2012, Pages 2203-2230

  Tandler, Nadine ^a,b   Mosch, Birgit ^a   Pietzsch, Jens ^a,b  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Diagnostic markers; Melanomata; Molecular targets; Pigment cells; Prognostic markers; S100 proteins; Serological markers; Skin cancer; Stem cell like markers; Therapy monitoring

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CALVASCULIN; CELL ADHESION MOLECULE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; DACARBAZINE; GALECTIN 3; GLYCOPROTEIN GP 39; INTERLEUKIN 2; KISSPEPTIN; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; MELANOMA ANTIGEN; MELANOMA INHIBITORY ACTIVITY; MONOPHENOL MONOOXYGENASE; OSTEOPONTIN; PROTEIN S 100; PROTEIN S100A2; PROTEIN S100B; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VEMURAFENIB;

CANCER STAGING; CELL CYCLE REGULATION; CELL PROLIFERATION; CRYSTALLIZATION; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; EPIGENETICS; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INCIDENCE; MELANOMA; MUTAGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME;

HUMANS; MELANOMA; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872684765     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-012-1409-5     Document Type: Review

References (258)

1. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856-859
2. Abdou AG, Hammam MA, Farargy SE, Farag AG, El Shafey EN, Farouk S, Elnaidany NF (2010) Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Am J Dermatopathol 32(8):809-814
3. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O (2002) Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 43(1):1-8 (Pubitemid 34032432)
4. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M, Linares J, Serrano S, Saez-Castillo AI, Sanchez L et al (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67(7):3450-3460 (Pubitemid 46724886)
5. Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C et al (2009) ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol 129(6):1471-1482
6. Andersen LB, Xia L, Stoll S, Zhao X, Elder JT (1996) Lineagespecific CaN19 expression in human skin: lack of expression in normal melanocytes. J Dermatol Sci 12(1):69-72 (Pubitemid 26155456)
7. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM (2004) Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17(8):990-997 (Pubitemid 38993784)
8. Arenberger P, Arenbergerova M, Gkalpakiotis S, Lippert J, Stribrna J, Kremen J (2008) Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-Associated antigens: A novel possible staging method. J Eur Acad Dermatol Venereol 22(1):56-64
9. Arumugam T, Logsdon CD (2011) S100P: A novel therapeutic target for cancer. Amino Acids 41(4):893-899
10. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD (2004) S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 279(7):5059-5065 (Pubitemid 38220521)
11. Arumugam T, Simeone DM, Van Golen K, Logsdon CD (2005) S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 11(15):5356-5364 (Pubitemid 41060808)
12. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206
13. Balch CM, Gershenwald JE, Soong SJ, Thompson JF (2011) Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 104(4):379-385
14. Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S (2002) Comparison of prognostic significance of serum 5-SCysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8(3):183-187 (Pubitemid 35407638)
15. Banfalvi T, Gilde K, Gergye M, Boldizsar M, Kremmer T, Otto S (2003) Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer 39(2):164-169 (Pubitemid 36057065)
16. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, Akslen LA, Armstrong BK, Avril MF, Azizi E et al (2011) Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 43(11):1108-1113
17. Becker T, Gerke V, Kube E, Weber K (1992) S100P, a novel Ca(2?)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2? binding properties. Eur J Biochem 207(2):541-547
18. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T (2009) COX-2 expression in malignant melanoma: A novel prognostic marker? Melanoma Res 19(1):8-16
19. Bernard JJ, Cowing-Zitron C, Nakatsuji T, Muehleisen B, Muto J, Borkowski AW, Martinez L, Greidinger EL, Yu BD, Gallo RL (2012) Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med 18:1286-1289
20. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R (2006) Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 213(3):187-191 (Pubitemid 44567827)
21. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E et al (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41(8):920-925
22. Black S, Kushner I, Samols D (2004) C-reactive Protein. J Biol Chem 279(47):48487-48490 (Pubitemid 39625721)
23. Bloethner S, Scherer D, Drechsel M, Hemminki K, Kumar R (2009) Malignant melanoma-A genetic overview. Actas Dermosifiliogr 100(Suppl 1):38-51
24. Boissy RE (1988) The melanocyte. Its structure, function, and subpopulations in skin, eyes, and hair. Dermatol Clin 6(2):161-173
25. Bosserhoff AK (2006) Novel biomarkers in malignant melanoma. Clin Chim Acta 367(1-2):28-35
26. Bosserhoff AK, Kuster H, Hein R (2004) Elevated MIA levels in the serum of pregnant women and of children. Clin Exp Dermatol 29(6):628-629 (Pubitemid 39573653)
27. Bouwhuis MG, Suciu S, Kruit W, Sales F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Lienard D, Eggermont AM et al (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952. Eur J Cancer 47(3):361-368
28. Brochez L, Naeyaert JM (2000) Serological markers for melanoma. Br J Dermatol 143(2):256-268 (Pubitemid 30650391)
29. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, Johnson VE, Hwu WJ (2012) PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol 198(4):902-908
30. Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW (2012) Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer 48(6):865-874
31. Buljan M, Situm M, Tomas D, Milosevic M, Kruslin B (2011) Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol 25(10):1174-1181
32. Caron J, Mange A, Guillot B, Solassol J (2009) Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol 135(9):1257-1264
33. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G (2000) T-cell recognition of melanoma-Associated antigens. J Cell Physiol 182(3):323-331 (Pubitemid 30054365)
34. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516
35. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X et al (2008) Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997-1006
36. Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, Neese PY, Merrill P, Petroni GR, Slingluff CL Jr (2005) Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 28(4):412-419 (Pubitemid 40962336)
37. Chung MH, Gupta RK, Essner R, Ye W, Yee R, Morton DL (2002) Serum TA90 immune complex assay can predict outcome after resection of thick ([or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol 9(2):120-126 (Pubitemid 34259696)
38. Cruz C, Teule A, Caminal JM, Blanco I, Piulats JM (2011) Uveal melanoma and BRCA1/BRCA2 genes: A relationship that needs further investigation. J Clin Oncol 29(34):827-829
39. Dallaglio K, Marconi A, Pincelli C (2012) Survivin: A dual player in healthy and diseased skin. J Invest Dermatol 132(1):18-27
40. Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, PierottiMA, Parmiani G, RodolfoM(2007)Detection of mutated BRAFV600E variant in circulatingDNAof stage III-IV melanoma patients. Int J Cancer 120(11):2439-2444 (Pubitemid 46642132)
41. Davey GE, Murmann P, Hoechli M, Tanaka T, Heizmann CW (2000) Calcium-dependent translocation of S100A11 requires tubulin filaments. Biochim Biophys Acta 1498(2-3):220-232
42. Davey GE, Murmann P, Heizmann CW (2001) Intracellular Ca2? and Zn2? levels regulate the alternative cell density-dependent secretion of S100B in human glioblastoma cells. J Biol Chem 276(33):30819-30826
43. de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Brocker EB, Renard N, Eggermont AM, van Muijen GN, Ruiter DJ (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffinembedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 193(1):13-20 (Pubitemid 32051107)
44. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891-1896 (Pubitemid 29269262)
45. Deichmann M, Kahle B, Moser K, Wacker J, Wust K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91(4):699-702 (Pubitemid 39141627)
46. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, Hauptmann S (2001) Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61(1):303-308 (Pubitemid 32095731)
47. Diaz-Lagares A, Alegre E, Arroyo A, Gonzalez-Cao M, Zudaire ME, Viteri S, Martin-Algarra S, Gonzalez A (2011) Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 32(6):1155-1161
48. Dickson PV, Gershenwald JE (2011) Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 20(1):1-17
49. Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P et al (2007) Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol 28(5):264-272 (Pubitemid 350165832)
50. Donato R (2007) RAGE: A single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 7(8):711-724
51. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, Tubaro C, Giambanco I (2009) S100B's double life: intracellularregulator and extracellular signal. Biochim Biophys Acta 1793(6):1008-1022
52. Dumaz N (2011) Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small Gtpases 2(5):289-292
53. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, Brummer J (2004) CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 165(5):1781-1787 (Pubitemid 39435175)
54. Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A (2008) Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31(7):380-384 (Pubitemid 351967575)
55. Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A (2010) SerumS100BandLDHare not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 30(5):1799-1805
56. Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A (2012) Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 48(5):695-702
57. Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, Hauschild A, Brenner H, Katalinic A, the GSWG (2012) Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol. doi:10.1111/j.1365-2133.2012. 11039.x
58. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW (2002) Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188:136-146 (Pubitemid 35398871)
59. Essler M, Link A, Belloni B, Mirceva V, Souvatzoglou M, Thaler M, Haller B, Hein R, Krause BJ (2011) Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-Associated mortality in patients with high risk melanoma. PLoS ONE 6(9):24632-24638
60. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL (2007) A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest 25(5):285-293 (Pubitemid 47185072)
61. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP et al (2008) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68(8):2745-2754 (Pubitemid 351556272)
62. Ferrucci PF, Tosti G, di Pietro A, Passoni C, Pari C, Tedeschi I, Cataldo F, Martinoli C, Testori A (2012) Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment. Curr Top Med Chem 12(1):11-31
63. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S (2009) Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 27(13):2199-2208
64. Forgber M, Trefzer U, Sterry W, Walden P (2009) Proteome serological determination of tumor-Associated antigens in melanoma. PLoS ONE 4(4):5199-5210
65. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, Volkenandt M, Ganser A, Atzpodien J (1998) Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78(1):40-45 (Pubitemid 28276767)
66. Friedman EB, Shang S, Vega-Saenz de Miera E, Fog JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E et al (2012) Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 10(1):155-161
67. Fullen DR, Reed JA, Finnerty B, McNutt NS (2001) S100A6 expression in fibrohistiocytic lesions. J Cutan Pathol 28(5): 229-234 (Pubitemid 32391822)
68. Fusi A, Reichelt U, Busse A, Ochsenreither S, Rietz A, Maisel M, Keilholz U (2011) Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol 131(2):487-494
69. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97(7):1737-1745 (Pubitemid 36350717)
70. Garnier JP, Letellier S, Cassinat B, Lebbe C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B et al (2007) Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43(4):816-821 (Pubitemid 46502913)
71. Gaudi S, Messina JL (2011) Molecular bases of cutaneous and uveal melanomas. Patholog Res Int 2011:159421
72. Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A (1981) S100 protein: A marker for human malignant melanomas? Lancet 317(8225):869-871 (Pubitemid 11099318)
73. Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F, Group EM (2001) On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 94(4):586-590
74. Gibadulinova A, Tothova V, Pastorek J, Pastorekova S (2011) Transcriptional regulation and functional implication of S100P in cancer. Amino Acids 41(4):885-892
75. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7): 709-718 (Pubitemid 43247141)
76. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, Bangert J, Harmon JM, Fujiwara H, Koki A et al (2003) Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2(6): 713-718
77. Green AC, Wallingford SC, McBride P (2011) Childhood exposure to ultraviolet radiation and harmful skin effects: epidemiological evidence. Prog Biophys Mol Biol 107(3):349-355
78. Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS (2012) Epigenetic biomarkers in skin cancer. Cancer Lett. doi: 10.1016/j.canlet.2012.1001.1020
79. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA (2009) Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 129(6):1483-1488
80. Haluska F, Pemberton T, Ibrahim N, Kalinsky K (2007) The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 34(6):546-554 (Pubitemid 350236312)
81. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC (2003) Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 13(1):45-49 (Pubitemid 36269813)
82. Hara H, Walsh N, Yamada K, Jimbow K (1994) High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol 102(4):501-505 (Pubitemid 24117192)
83. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410-1413
84. Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37(7):512-518 (Pubitemid 38845014)
85. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E (1999) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9(2):155-161 (Pubitemid 29331524)
86. Helfman DM, Kim EJ, Lukanidin E, Grigorian M (2005) The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92(11):1955-1958 (Pubitemid 40897415)
87. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15(7):673-682
88. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, Ito S, Ono T (1997) Serum levels of sICAM-1 and 5-Scysteinyldopa as markers of melanoma progression. Melanoma Res 7(1):58-62 (Pubitemid 27110283)
89. Hiripi E, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, Sirri E, Brenner H, Group GCSW (2012) Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol 23(2):472-479
90. Hoashi T, Tamaki K, Hearing VJ (2010) The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J 24(3):916-930
91. HodisE,Watson IR, KryukovGV,Arold ST, Imielinski M,Theurillat JP, Nickerson E, Auclair D, Li L, Place C et al (2012) A landscape of driver mutations in melanoma. Cell 150(2):251-263
92. Hofmann MA, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I, Voit C, Trefzer U (2009) Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 19(1):17-23
93. Hofmann MA, Schicke B, Fritsch A, Biesold S, Gussmann F, Kuchler I, Voit C, Trefzer U (2011) Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. J Dermatol 38(9):880-886
94. Howell PM Jr, Li X, Riker AI, Xi Y (2010) MicroRNA in melanoma. Ochsner J 10(2):83-92
95. Hsieh H-L, Schafer BW, Cox JA, Heizmann CW (2002) S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells. J Cell Sci 115(15):3149-3158
96. Hussein MR, Haemel AK, Wood GS (2003) Apoptosis and melanoma: molecular mechanisms. J Pathol 199(3):275-288 (Pubitemid 36266850)
97. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231(1):20-27 (Pubitemid 43063974)
98. Johansen JS, Williamson MK, Rice JS, Price PA (1992) Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7(5):501-512
99. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15(2):194-202 (Pubitemid 43342164)
100. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff A (2001) Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol 22(1):54-58
101. Jury CS, McAllister EJ, MacKie RM (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 143(2): 269-274 (Pubitemid 30650392)
102. Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19(5):275-282
103. Kanavy HE, Gerstenblith MR (2011) Ultraviolet radiation and melanoma. Semin Cutan Med Surg 30(4):222-228
104. Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M et al (2011) The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 61(3):187-193
105. Karnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B (1997) S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2- carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 7(5):393-399 (Pubitemid 27508730)
106. Kefford R (2009) Melanoma. In: Schwab M (ed) Encyclopedia of Cancer. Springer, Berlin, pp 1804-1807
107. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL (2001) Tumor-Associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 19(4):1176-1182 (Pubitemid 32176296)
108. Khan MK, Khan N, Almasan A, Macklis R (2011) Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther 4:137-148
109. Kim HE, Symanowski JT, Samlowski EE, Gonzales J, Ryu B (2010) Quantitativemeasurement of circulating lymphoid-specific helicase (HELLS) gene transcript: A potential serum biomarker for melanoma metastasis. Pigment Cell Melanoma Res 23(6):845-848
110. Kirkin AF, Dzhandzhugazyan K, Zeuthen J (1998) Melanomaassociated antigens recognized by cytotoxic T lymphocytes. APMIS 106(7):665-679 (Pubitemid 28383441)
111. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17(8):2417-2425
112. Kniess T, Laube M, Bergmann R, Sehn F, Graf F, Steinbach J, Wuest F, Pietzsch J (2012) Radiosynthesis of a 18F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo. Bioorg Med Chem 20(11):3410-3421
113. Kounalakis N, Goydos JS (2005) Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management. Curr Oncol Rep 7(5):377-382 (Pubitemid 41309552)
114. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, Wang HJ, Hseuh E, O'Day SJ, Hoon DS (2005) Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 51(6):981-988 (Pubitemid 40740878)
115. Krogh M, Christensen IJ, Bouwhuis M, Johansen JS, Schmidt H, Hansson J, Aamdal S, Testori A, Eggermont AM, Bastholt L (2010) Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. J Clin Oncol 2010 ASCO Annual Meeting 28(15s):abstract 8587
116. Kruijff S, Hoekstra HJ (2012) The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol 38(4):281-285
117. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ (2009) S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 16(12):3455-3462
118. Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJ, Hospers GA, Hoekstra HJ (2012) Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Ann Surg Oncol 19(2):620-626
119. Kuzbicki L, Sarnecka A, Chwirot BW (2006) Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 16(1):29-36 (Pubitemid 44133048)
120. Kuzbicki L, Lange D, Straczynska-Niemiec A, Chwirot BW (2012) The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions. Melanoma Res 22(1):70-76
121. Laga AC, Murphy GF (2010) Cellular heterogeneity in vertical growth phase melanoma. Arch Pathol Lab Med 134(12): 1750-1757
122. Larue L, Delmas V (2006) The WNT/Beta-catenin pathway in melanoma. Front Biosci 11:733-742 (Pubitemid 43258176)
123. Leclerc E (2011) The roles of S100 proteins and RAGE in melanoma, breakthroughs in melanoma research. In: Yohei Tanaka (ed) InTech; ISBN: 978-953-307-291-3. http://www.intechopen.com/books/breakthroughs-in-melanoma- research/the-roles-of-s100-proteins-And-rage-in-melanoma
124. Leclerc E, Heizmann CW, Vetter SW (2009) RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen Physiol Biophys 28:65-75
125. Leidinger P, Keller A, Borries A, Reichrath J, Rass K, Jager SU, Lenhof HP, Meese E (2010) High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 10:212-262
126. Lesniak W, Slomnicki LP, Filipek A (2009) S100A6-new facts and features. Biochem Biophys Res Commun 390(4):1087-1092
127. Letellier S, Garnier JP, Spy J, Stoitchkov K, Le Bricon T, Baccard M, Revol M, Kerneis Y, Bousquet B (1999) Development of metastases in malignant melanoma is associated with an increase in the plasma L-dopa/L-tyrosine ratio. Melanoma Res 9(4):389-394 (Pubitemid 29407072)
128. Leyvraz S, Keilholz U (2012) Ocular melanoma: what's new? Curr Opin Oncol 24(2):162-169
129. Li J, Cheng Y, Tai D, Martinka M, Welch DR, Li G (2011) Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 30(8):896-906
130. Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ (2010) The calciumbinding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem 285(35):27487-27498
131. Logsdon CD, Fuentes M, Huang E, Arumugam T (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7:777-789
132. Ma J, Lin JY, Alloo A, Wilson BJ, Schatton T, Zhan Q, Murphy GF, Waaga-Gasser AM, Gasser M, Stephen Hodi F et al (2010) Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402(4):711-717
133. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O (1997) Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 74(4):464-469 (Pubitemid 27400171)
134. Maier T, Laubender RP, Sturm RA, Klingenstein A, Korting HC, Ruzicka T, Berking C (2011) Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol 26(9):1084-1091
135. Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD et al (2012) Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer 48(8):1167-1175
136. Mancini AJ (2004) Skin. Pediatrics 113(4 Suppl):1114-1119 (Pubitemid 38443357)
137. Mansh M (2011) Ipilimumab and cancer immunotherapy: A new hope for advanced stage melanoma. Yale J Biol Med 84(4):381-389
138. Marchetti D, Denkins Y, Reiland J, Greiter-Wilke A, Galjour J, Murry B, Blust J, Roy M (2003) Brain-metastatic melanoma: A neurotrophic perspective. Pathol Oncol Res 9(3):147-158 (Pubitemid 37429493)
139. Marquez-Rodas I, Martin Algarra S, Aviles Izquierdo JA, Custodio Cabello S, Martin M (2011) A new era in the treatment of melanoma: from biology to clinical practice. Clin Transl Oncol 13(11):787-792
140. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M (1999) Thin cutaneous malignant melanomas (\or =1.5 mm): identification of risk factors indicative of progression. Cancer 85(5):1067-1076 (Pubitemid 29115585)
141. Massi D, Landriscina M, Piscazzi A, Cosci E, Kirov A, Paglierani M, Di Serio C, Mourmouras V, Fumagalli S, Biagioli M et al (2010) S100A13 is a new angiogenic marker in human melanoma. Mod Pathol 23(6):804-813
142. Matsuzaki Y, Hashimoto S, Fujita T, Suzuki T, Sakurai T, Matsushima K, Kawakami Y (2005) Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). J Immunother 28(1):10-19 (Pubitemid 40075933)
143. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT et al (2012) Marked, homogeneous, and early [18F]fluorodeoxyglucosepositron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30(14): 1628-1634
144. Medic S, Pearce RL, Heenan PJ, Ziman M (2007) Molecular markers of circulating melanoma cells. Pigment Cell Res 20(2):80-91 (Pubitemid 46439517)
145. Mendoza L, Olaso E, Anasagasti MJ, Fuentes AM, Vidal-Vanaclocha F (1998) Mannose receptor-mediated endothelial cell activation contributes to B16 melanoma cell adhesion and metastasis in liver. J Cell Physiol 174(3):322-330 (Pubitemid 28068709)
146. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA et al (2009) Cyclooxygenase 2 (COX2) and peroxisome proliferatoractivated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res:848645. doi: 10.841155/842010/848645
147. Meyerhoffer S, Lindberg Z, Hager A, Kagedal B, Rosdahl I (1998) Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children. Acta Derm Venereol 78(1):31-35 (Pubitemid 28103675)
148. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23(22):5088-5093 (Pubitemid 46224016)
149. Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, Serpero L, Gazzolo D (2012) The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem 120(5):644-659
150. Mintz B (1971) Clonal basis of mammalian differentiation. Symp Soc Exp Biol 25:345-370
151. Mirk P, Treglia G, Salsano M, Basile P, Giordano A, Bonomo L (2011) Comparison between F-fluorodeoxyglucose positron emission tomography and sentinel lymph node biopsy for regional lymph nodal staging in patients with melanoma: A review of the literature. Radiol Res Pract:912504. doi: 10.911155/912011/912504
152. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513-10518
153. Mocellin S, Zavagno G, Nitti D (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-Analysis. Int J Cancer 123(10):2370-2376
154. Molina R, Navarro J, Filella X, Castel T, Ballesta AM (2002) S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23(1):39-44 (Pubitemid 34225020)
155. Mooi WJ, Krausz T (2009) Melanocytic tumors. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin, pp 1803-1804
156. Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19(6):739-744
157. Mouawad R, Spano JP (2009) Khayat D (2010) Old and new serological biomarkers in melanoma: where we are in. Melanoma Res 20(2):67-76
158. Mouawad R, Soubrane C, Khayat D (2005) Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A,C,D) and their receptors (R1, R2 and R3) in advanced melanomapatients. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25 (18S):8540
159. Mouret S, Baudouin C, Charveron M, Favier A, Cadet J, Douki T (2006) Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc Natl Acad Sci USA 103(37):13765-13770 (Pubitemid 44413982)
160. Muller-Decker K, Furstenberger G (2007) The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 46(8):705-710 (Pubitemid 47255191)
161. Nash KT, Welch DR (2006) The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 11:647-659 (Pubitemid 43258169)
162. Neuss H, Koplin G, Raue W, Reetz C, Mall JW (2011) Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases-A prospective study in 231 patients. Acta Chir Belg 111(4):214-218
163. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6(3):388-394
164. Nicolaou A, Estdale SE, Tsatmali M, Herrero DP, Thody AJ (2004) Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone. FEBS Lett 570(1-3): 223-226 (Pubitemid 38900985)
165. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S (2002) High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 97(4):432-438 (Pubitemid 34027800)
166. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11(14):5158-5166 (Pubitemid 41003701)
167. Nonaka D, Chiriboga L, Rubin BP (2008) Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol 35(11):1014-1019
168. Norgaard C, Glud M, Gniadecki R (2011) Are all melanomas dangerous? Acta Derm Venereol 91(5):499-503
169. Nyormoi O, Bar-Eli M (2003) Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 20(3):251-263 (Pubitemid 36513229)
170. Oberholzer PA, Urosevic M, Steinert HC, Dummer R (2008) Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography. Dermatology 217(4):351-355
171. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 12(4):325-334 (Pubitemid 34816437)
172. Palmer SR, Erickson LA, Ichetovkin I, Knauer DJ, Markovic SN (2011) Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc 86(10):981-990
173. Patel P, Finger PT (2012) Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis. Am J Ophthalmol 153(4):661-668
174. Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, Laurent R, Humbert P, Aubin F (2005) Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol 152(4):685-689 (Pubitemid 40571300)
175. Peric B, Zagar I, Novakovic S, Zgajnar J, HocevarM(2011) Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer 11:328. doi:10.1186/1471-2407-1111-1328
176. Perrotta R, Bevelacqua Y, Malaguarnera G, Paladina I, Giordano M, Malaguarnera M (2010) Serum markers of cutaneous melanoma. Front Biosci (Elite Ed) 2:1115-1122
177. Petersson S, Shubbar E, Enerback L, Enerback C (2009) Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Res 19(4):215-225
178. Pfeifer GP, Besaratinia A (2012) UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci 11(1):90-97
179. Pietzsch J (2011) S100 proteins in health and disease. Amino Acids 41(4):755-760
180. Pinon P, Wehrle-Haller B (2011) Integrins: versatile receptors controlling melanocyte adhesion, migration and proliferation. Pigment Cell Melanoma Res 24(2):282-294
181. Pinzani P, Salvianti F, Zaccara S, Massi D, De Giorgi V, Pazzagli M, Orlando C (2011) Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta 412(23-24):2141-2145
182. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16(2):159-178 (Pubitemid 40616114)
183. Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardo T, Fierro MT, Cavallo F, Savoia P, Bernengo MG (2007) Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res 17(2):75-82 (Pubitemid 46673900)
184. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM (2008) Cathepsin K in melanoma invasion. J Invest Dermatol 128(9):2281-2288
185. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C (1997) Myeloid-related protein (MRP) 8 and MRP14, calciumbinding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 272(14):9496-9502 (Pubitemid 27154966)
186. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1): 144-150
187. Redondo P, Lloret P, Idoate M, Inoges S (2005) Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30(5):541-545 (Pubitemid 41076024)
188. Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC (2006) Cytoplasmic melanoma-Associated antigen (CYT-MAA) serum level in patients with melanoma: A potential marker of response to immunotherapy? Int J Cancer 119(1):157-161
189. Riker AI, Zea N, Trinh T (2010) The epidemiology, prevention, and detection of melanoma. Ochsner J 10(2):56-65
190. Robertson FM (2009) Skin carcinogenesis. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin, pp 2751-2755
191. Rotte A, Martinka M, Li G (2012) MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol (Dordr) 35(3):207-216
192. Roy M, Marchetti D (2009) Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem 106(2):200-209
193. Sabel MS, Liu Y, Lubman DM (2011) Proteomics in melanoma biomarker discovery: great potential, many obstacles. Int J Proteomics 181890. doi:10.181155/182011/181890
194. Saleh D, Peach AH (2011) Ultra-late recurrence of malignant melanoma after 40 years of quiescent disease. J Surg Oncol 103(3):290-291
195. Samija I, Lukac J, Maric-Brozic J, Buljan M, Alajbeg I, Kovacevic D, Situm M, Kusic Z (2010) Prognostic value of microphthalmiaassociated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res 20(4):293-302
196. Sang MX, Wang LF, Ding CY, Zhou XL, Wang B, Wang L, Lian YS, Shan BE (2011) Melanoma-Associated antigen genes-An update. Cancer Lett 302(2):85-90
197. Santonocito C, Concolino P, Lavieri MM, Ameglio F, Gentileschi S, Capizzi R, Rocchetti S, Amerio P, Castagnola M, Zuppi C et al (2005) Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers. Clin Chim Acta 362(1-2):85-93
198. Sapoznik S, Ortenberg R, Schachter J, Markel G (2012) CEACAM1 in malignant melanoma: A diagnostic and therapeutic target. Curr Top Med Chem 12(1):3-10
199. Schmidt H, Sorensen BS, Fode K, Nexo E, von der Maase H (2005) Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res 15(5):409-416 (Pubitemid 41558951)
200. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006a) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5):1130-1139
201. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H (2006b) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24(5):798-804 (Pubitemid 46622047)
202. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11(6):426-437
203. Sedaghat F, Notopoulos A (2008) S100 protein family and its application in clinical practice. Hippokratia 12(4):198-204
204. Shinozaki M, Fujimoto A, Morton DL, Hoon DS (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10(5):1753-1757 (Pubitemid 38435567)
205. Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118(9): 1881-1885
206. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, Jacob S, Gal M, Michal L (2012) Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 290536. doi:10.291155/292012/ 290536
207. Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH (2006) Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 90:243-295 (Pubitemid 43786236)
208. Solassol J, Du-Thanh A, Maudelonde T, Guillot B (2011) Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma. Int J Biol Markers 26(2):82-87
209. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63(7):1639-1643 (Pubitemid 36373656)
210. Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, Parsons PG, Schmidt C, Sturm RA, Hayward NK (2010) Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 5(3):e9685. doi:10.1371/journal.pone. 0009685
211. Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ, Graham N, Roberts C, Ryan G, Uppal H et al (2011) Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther 18(6):584-593
212. Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T (2003) Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res 13(6):587-593 (Pubitemid 38296896)
213. Takikawa M, Akiyama Y, Ashizawa T, Yamamoto A, Yamazaki N, Kiyohara Y, Oku N, Yamaguchi K (2009) Identification of melanoma-specific serological markers using proteomic analyses. Proteomics Clin Appl 3(5):552-562
214. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27(1):38-44
215. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P, Fridman WH (1994) Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69(5):911-913 (Pubitemid 24140673)
216. Tas F, Duranyildiz D, Oguz H, Disci R, Kurul S, Yasasever V, Topuz E (2005) Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol 22(1):39-44 (Pubitemid 40647228)
217. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2008) Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol 25(4):431-436
218. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20(10):2530-2536 (Pubitemid 34525740)
219. Tillett WS, Francis T (1930) Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 52(4):561-571
220. Truzzi F, Marconi A, Lotti R, Dallaglio K, French LE, Hempstead BL, Pincelli C (2008) Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. J Invest Dermatol 128(8):2031-2040 (Pubitemid 352001206)
221. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122(2): 337-341 (Pubitemid 38281053)
222. Tsoporis JN, Mohammadzadeh F, Parker TG (2011) S100B: A multifunctional role in cardiovascular pathophysiology. Amino Acids 41(4):843-847
223. Tsukamoto K, Ueda M, Hirata S, Osada A, Kitamura R, Takahashi T, Ichihashi M, Shimada S (2000) gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients. J Dermatol Sci 23(2):126-131 (Pubitemid 30243160)
224. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577-583 (Pubitemid 32112873)
225. Ulrich J, van Akkooi AJ, Eggermont AM, Voit C (2011) New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). Expert Rev Anticancer Ther 11(11):1693-1701
226. Uong A, Zon LI (2010) Melanocytes in development and cancer. J Cell Physiol 222(1):38-41
227. Vallacchi V, Rivoltini L, Rodolfo M (2011) BRAF V600E mutated gene variant as a circulating molecular marker in metastatic melanoma patients, research on melanoma-A glimpse into current directions and future trends. InTech; ISBN: 978-953-307-293-7. http://www.intechopen.com/books/research- onmelanoma-A-glimpse-into-current-directions-And-future-trends/ braf-v600e-mutated-gene-variant-As-A-circulating-molecularmarker-in-metastatic- melanoma-patients
228. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191-2199
229. Vendittelli F, Santonocito C, Paradisi A, Romitelli F, Concolino P, Silveri SL, Sisto T, Capizzi R, Catricala C, Mule A et al (2009) A new standardized absolute quantitative RT-PCR method for detection of tyrosinase mRNAs in melanoma patients: technical and operative instructions. Clin Chim Acta 409(1-2): 100-105
230. Vereecken P, Heenen M (2006) Serum galectin-3 in advanced melanoma patients: A hypothesis on a possible role in melanoma progression and inflammation. J Int Med Res 34(1):119-120
231. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G, Heenen M (2009) Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 19(5):316-320
232. Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF (2012) A synopsis of serum biomarkers in cutaneous melanoma patients. Dermatol Res Pract 2012:260643. doi:10.261155/2620 12/260643
233. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR (2005) Presence and prognostic significance of melanoma-Associated antigens CYTMAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 125(3):526-531
234. Vermeeren L, Valdes Olmos RA, Klop WM, van der Ploeg IM, Nieweg OE, Balm AJ, van den Brekel MW (2011) SPECT/CT for sentinel lymph node mapping in head and neck melanoma. Head Neck 33(1):1-6
235. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99(2):157-166 (Pubitemid 34309470)
236. Vihinen PP, Hilli J, Vuoristo MS, Syrjanen KJ, Kahari VM, Pyrhonen SO (2007) Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 46(5):678-684 (Pubitemid 46911902)
237. Visus C, Andres R, Mayordomo JI, Martinez-Lorenzo MJ, Murillo L, Saez-Gutierrez B, Diestre C, Marcos I, Astier P, Godino J et al (2007) Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res 17(2):83-89 (Pubitemid 46673901)
238. Vuoristo MS, Kellokumpu-Lehtinen P, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Laine S (2000) Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol 39(7):877-879
239. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37(13):1629-1634 (Pubitemid 32778608)
240. Wang G, Platt-Higgins A, Carroll J, de Rudland Silva S, Winstanley J, Barraclough R, Rudland PS (2006) Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 66(2):1199-1207 (Pubitemid 43165991)
241. Warner CL, Cockerell CJ (2011) The new seventh edition American Joint Committee on Cancer staging of cutaneous non-melanoma skin cancer: A critical review. Am J Clin Dermatol 12(3): 147-154
242. Weber G (2007) Molecular mechanisms of cancer: epithelial tumors. Springer, Netherlands, pp 441-524
243. Weterman MA, Stoopen GM, van Muijen GN, Kuznicki J, Ruiter DJ, Bloemers HP (1992) Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res 52(5):1291-1296
244. Weyers W (2012) The 'epidemic' of melanoma between under-And overdiagnosis. J Cutan Pathol 39(1):9-16
245. Whiteman DC, Pavan WJ, Bastian BC (2011) The melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 24(5):879-897
246. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G (1997) Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 57(22):5073-5076 (Pubitemid 27498122)
247. Wisco OJ, Sober AJ (2012) Prognostic factors for melanoma. Dermatol Clin 30(3):469-485
248. Wolf S, Haase-Kohn C, Pietzsch J (2011) S100A2 in cancerogenesis: A friend or a foe? Amino Acids 41(4):849-861
249. Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M, Kirsch K (2001) Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol 127(10):631-635 (Pubitemid 32778654)
250. Woodman SE, Davies MA (2010) Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568-574
251. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P (2004) Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23(30):5215-5226 (Pubitemid 38980354)
252. Xie R, Schlumbrecht MP, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR (2009) S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest 89(8):937-947
253. Yang Q, O'Hanlon D, Heizmann CW, Marks A (1999) Demonstration of heterodimer formation between S100B and S100A6 in the yeast two-hybrid system and human melanoma. Exp Cell Res 246(2):501-509 (Pubitemid 29394013)
254. Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu W, Lin Y, Zhou Z, Qu J (2008) Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 49(2):497-504
255. Yeh I, Bastian BC (2009) Genome-wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res 22(5):527-528
256. Yuspa SH (1986) Cutaneous chemical carcinogenesis. J Am Acad Dermatol 15(5 Pt 1):1031-1044 (Pubitemid 17176818)
257. Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X (2011) IL8 and Cathepsin B as melanoma serum biomarkers. Int J Mol Sci 12(3):1505-1518
258. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C et al (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124(5):1044-1052 (Pubitemid 40629107)